TY - JOUR
T1 - The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine
T2 - Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
AU - Lipton, Richard B.
AU - Seng, Elizabeth K.
AU - Chu, Min Kyung
AU - Reed, Michael L.
AU - Fanning, Kristina M.
AU - Adams, Aubrey Manack
AU - Buse, Dawn C.
N1 - Funding Information:
Dr. Buse has received grant support and honoraria from AbbVie, Amgen, Avanir, Eli Lilly and Company, Promius and Teva, although no payments were made by any of these companies for work writing abstracts, scientific presentations, or manuscripts. She is on the editorial board of . Dr. Seng receives research support from NINDS (K23 NS096107 PI: Seng); has consulted for Eli Lilly and GlaxoSmithKline; and has received honoraria from Haymarket Media. Dr. Chu has received honoraria from AbbVie Korea and YuYu Pharma, Inc. Dr. Reed is Managing Director of Vedanta Research, which has received research funding from AbbVie, Amgen, Dr. Reddy's Laboratories/Promius, and Eli Lilly, and grants from the National Headache Foundation. Vedanta Research has received funding directly from AbbVie for work on the CaMEO Study. Dr. Fanning is an employee of Vedanta Research, which has received research funding from AbbVie, Amgen, Dr. Reddy's Laboratories/Promius, and Eli Lilly, and grants from the National Headache Foundation. Vedanta Research has received funding directly from AbbVie for work on the CaMEO Study. Dr. Manack Adams is a full‐time employee of AbbVie and owns stock in the company. Dr. Lipton serves on the editorial boards of and , and as senior advisor to . He has received research support from the NIH. He also receives support from the Migraine Research Foundation and the National Headache Foundation. He has reviewed for the NIA and NINDS and serves as consultant, advisory board member, or has received honoraria from Alder, AbbVie, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy's Laboratories, electroCore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Novartis, Pernix, Pfizer, Supernus, Teva, Vector, and Vedanta. He receives royalties from (eighth Edition, Oxford University Press), Informa, and Wiley. He holds stock options in Biohaven and eNeura Therapeutics. Conflict of Interest: Current Pain and Headache Reports Neurology Cephalalgia Headache Wolff's Headache
Funding Information:
This study was sponsored by Allergan (prior to its acquisition by AbbVie). Funding:
Publisher Copyright:
© 2020 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Objective: To examine the influences of depression and anxiety on headache-related disability in people with episodic migraine or chronic migraine. Background: Depression and anxiety are common comorbidities in people with migraine, especially among those with chronic migraine. Methods: This cross-sectional analysis of data from the longitudinal, internet-based Chronic Migraine Epidemiology and Outcomes Study assessed sociodemographic and headache features, and headache-related disability (Migraine Disability Assessment Scale). Four groups were defined based on scores from validated screeners for depression (9-item Patient Health Questionnaire) and anxiety (7-item Generalized Anxiety Disorder Scale): depression alone, anxiety alone, both, or neither. Results: Respondents (N = 16,788) were predominantly women (74.4% [12,494/16,788]) and white (84.0% [14,044/16,788]); mean age was 41 years. Depression was more likely in persons with chronic migraine vs episodic migraine (56.6% [836/1476] vs 30.0% [4589/15,312]; P <.001), as were anxiety (48.4% [715/1476] vs 28.1% 4307/15,312]; P <.001) and coexisting depression and anxiety (42.0% [620/1476] vs 20.8% [3192/15,312]; P <.001). After controlling for headache frequency and other covariates, depression alone, and anxiety alone were associated with 56.0% (rate ratio [RR], 1.56; 95% confidence interval [CI], 1.46-1.66) and 39.0% (RR, 1.39; 95% CI, 1.30-1.50) increased risks of moderate/severe migraine-related disability (both P <.001), respectively; the combination had an even greater effect on risk of moderate/severe disability (79.0% increase; RR, 1.79; 95% CI, 1.71-1.87; P <.001). Conclusions: Depression alone and anxiety alone are associated with greater headache-related disability after controlling for sociodemographic and headache features. Coexisting depression and anxiety are more strongly associated with disability than either comorbidity in isolation. Interventions targeting depression and anxiety as well as migraine itself may improve headache-related disability in people with migraine.
AB - Objective: To examine the influences of depression and anxiety on headache-related disability in people with episodic migraine or chronic migraine. Background: Depression and anxiety are common comorbidities in people with migraine, especially among those with chronic migraine. Methods: This cross-sectional analysis of data from the longitudinal, internet-based Chronic Migraine Epidemiology and Outcomes Study assessed sociodemographic and headache features, and headache-related disability (Migraine Disability Assessment Scale). Four groups were defined based on scores from validated screeners for depression (9-item Patient Health Questionnaire) and anxiety (7-item Generalized Anxiety Disorder Scale): depression alone, anxiety alone, both, or neither. Results: Respondents (N = 16,788) were predominantly women (74.4% [12,494/16,788]) and white (84.0% [14,044/16,788]); mean age was 41 years. Depression was more likely in persons with chronic migraine vs episodic migraine (56.6% [836/1476] vs 30.0% [4589/15,312]; P <.001), as were anxiety (48.4% [715/1476] vs 28.1% 4307/15,312]; P <.001) and coexisting depression and anxiety (42.0% [620/1476] vs 20.8% [3192/15,312]; P <.001). After controlling for headache frequency and other covariates, depression alone, and anxiety alone were associated with 56.0% (rate ratio [RR], 1.56; 95% confidence interval [CI], 1.46-1.66) and 39.0% (RR, 1.39; 95% CI, 1.30-1.50) increased risks of moderate/severe migraine-related disability (both P <.001), respectively; the combination had an even greater effect on risk of moderate/severe disability (79.0% increase; RR, 1.79; 95% CI, 1.71-1.87; P <.001). Conclusions: Depression alone and anxiety alone are associated with greater headache-related disability after controlling for sociodemographic and headache features. Coexisting depression and anxiety are more strongly associated with disability than either comorbidity in isolation. Interventions targeting depression and anxiety as well as migraine itself may improve headache-related disability in people with migraine.
KW - anxiety
KW - comorbidity
KW - depression
KW - headache-related disability
KW - migraine
UR - http://www.scopus.com/inward/record.url?scp=85089448930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089448930&partnerID=8YFLogxK
U2 - 10.1111/head.13914
DO - 10.1111/head.13914
M3 - Article
C2 - 33448374
AN - SCOPUS:85089448930
SN - 0017-8748
VL - 60
SP - 1683
EP - 1696
JO - Headache
JF - Headache
IS - 8
ER -